Condition: Hepatocellular Carcinoma · Sponsor: Abramson Cancer Center at Penn Medicine
A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)
This description comes directly from the study's public registry record.
Edgar Ben-Josef, MD · 215-615-6767 · edgar.ben-josef@pennmedicine.upenn.edu
Taylor Siegal · taylor.siegal@pennemdicine.upenn.edu
Always discuss trial participation with your own doctor first.
| Abramson Cancer Center of the University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05488522